Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients

Neoplasma

Volumn 61, Issue 4, 2014, Pages 439-446

  Puzovic, V ^a   Brcic, I ^b   Ranogajec, I ^c   Jakic Razumovic, J ^b  

^a Dubrovnik General Hospital   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Policlinic SUNCE ^*  (Croatia)

Author keywords

Breast cancer; ETS 1; Gelatinases; Prognosis; Transcription factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; TRANSCRIPTION FACTOR ETS 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904391004     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_054     Document Type: Article

References (35)

1. BENSON JR, JATOI I. The global breast cancer burden. Future Oncol 2012; 8: 697-702. http://dx.doi.org/10.2217/fon.12.61
2. HONRADO E, BENITEZ J, PALACIOS J. The molecular pathology of hereditary breast cancer genetic testing and therapeutic implications. Mod Pathol 2005; 18: 1305-20. http://dx.doi.org/10.1038/modpathol.3800453
3. SPAN PN, MANDERS P, HEUVEL JJ, THOMAS CM, BOSCH RR et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002; 21: 8506-9. http://dx.doi.org/10.1038/sj.onc.1206040
4. GILLES C, POLETTE M, BIREMBAUT P, BRUNNER N, THOMPSON EW. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997; 15: 519-26. http://dx.doi.org/10.1023/A:1018427027270
5. WASYLYK B, HAHN SL, GIOVANE A. The Ets family of transcription factors. Eur J Biochem 1993; 211: 7-18. http://dx.doi.org/10.1111/j.1432-1033.1993.tb19864.x
6. SETH A, WATSON DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-78. http://dx.doi.org/10.1016/j.ejca.2005.08.013
7. BUGGY Y, MAGUIRE TM, MCGREAL G, MCDERMOTT E, HILL AD et al. Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 2004; 91: 1308-15. http://dx.doi.org/10.1038/sj.bjc.6602128
8. LI R, PEI H, WATSON DK. Regulation of Ets function by protein-protein interactions. Oncogene 2000; 19: 6514-23. http://dx.doi.org/10.1038/sj.onc.1204035
9. HSU T, TROJANOWSKA M, WATSON DK. Ets proteins in biological control and cancer. J Cell Biochem 2004; 91: 896-903. http://dx.doi.org/10.1002/jcb.20012
10. SHEPHERD T, HASSELL JA. Role of Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 2001; 6: 129-40. http://dx.doi.org/10.1023/A:1009576801226
11. MYLONA EE, ALEXANDROU PT, GIANNOPOULOU IA, RAFAILIDIS PI, MARKAKI S et al. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. Cancer Detect Prev 2006; 30: 111-117. http://dx.doi.org/10.1016/j.cdp.2006.03.006
12. KARS MD, ISERI OD, GUNDUZ U. Drug resistant breast cancer cells overexpress ETS1 gene. Biomed Pharmacother 2010; 64: 458-462. http://dx.doi.org/10.1016/j.biopha.2010.01.008
13. KATAYAMA S, NAKAYAMA T, ITO M, NAITO S, SEKINE I. Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol 2005; 20: 119-26.
14. TOI M, ISHIGAKI S, TOMINAGA T. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 1998; 52: 113-24. http://dx.doi.org/10.1023/A:1006167202856
15. BARRETT JM, PUGILA MA, SINGH G, TOZER RG. Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. Breast Cancer Res Treat 2002; 72: 227-32. http://dx.doi.org/10.1023/A:1014993006190
16. BEHRENS P, ROTHE M, WELLMANN A, KRISCHLER J, WERNERT N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001; 194: 43-50. http://dx.doi.org/10.1002/path.844
17. SEMENTCHENKO VI, WATSON DK. Ets target genes: past, present and future. Oncogene 2000; 19: 6533-48. http://dx.doi.org/10.1038/sj.onc.1204034
18. Stetler-Stevenson WG, AZNAVOORIAN S, Li-Otta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73. http://dx.doi.org/10.1146/annurev.cb.09.110193.002545
19. CHABOTTAUX V, NOEL A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647-56. http://dx.doi.org/10.1007/s10585-007-9113-7
20. KESSENBROCK K, PLAKS V, WERB Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67. http://dx.doi.org/10.1016/j.cell.2010.03.015
21. Talvensaari-Mattila A, PAAKKO P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001; 65: 55-61. http://dx.doi.org/10.1023/A:1006458601568
22. SCORILAS A, KARAMERIS A, ARNOGIANNAKI N, ARDAVANIS A, BASSILOPOULOS P et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001; 84: 1488-96. http://dx.doi.org/10.1054/bjoc.2001.1810
23. DUFFY MJ, MAGUIRE TM, HILL A, MCDERMOTT E, OHIGGINS N. Metalloproteinases: role in breast carcino-genesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-7. http://dx.doi.org/10.1186/bcr65
24. KOHRMANN A, KAMMERER U, KAPP M, DIETL J, ANACKER J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009; 9: 188. http://dx.doi.org/10.1186/1471-2407-9-188
25. PELLIKAINEN JM, ROPPONEN KM, KATAJA VV, Kel-Lokoski JK, ESKELINEN MJ et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004; 10: 7621-8. http://dx.doi.org/10.1158/1078-0432.CCR-04-1061
26. LI HC, CAO DC, LIU Y, HOU YF, WU J et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 75-85. http://dx.doi.org/10.1007/s10549-004-1200-8
27. Talvensaari-Mattila A, PAAKKO P, Turpeen-Niemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 1270-5. http://dx.doi.org/10.1038/sj.bjc.6601238
28. TAKI M, VERSCHUEREN K, YOKOYAMA K, NAGAYAMA M, KAMATA N. Involvement of Ets-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial- mesenchymal transition in human squamous carcinoma cells. Int J Oncol 2006; 28: 487-96.
29. VAN DEN STEEN PE, DUBOIS B, NELISSEN I, RUDD PM, DWEK RA et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536. http://dx.doi.org/10.1080/10409230290771546
30. BENDRIK C, ROBERTSON J, GAULDIE J, DABROSIN C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res 2008; 68: 3405-12. http://dx.doi.org/10.1158/0008-5472.CAN-08-0295
31. SZABO KA, SINGH G. Modulation of monocyte matrix metal-loproteinase-2 by breast adenocarcinoma cells. Breast Cancer Res 2005; 7: 661-8. http://dx.doi.org/10.1186/bcr1261
32. CHANG C, WERB Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: 37-43. http://dx.doi.org/10.1016/S0962-8924(01)02122-5
33. NIEMIEC J, ADAMCZYK A, MALECKI K, AMBICKA A, RYS J. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. Clin Breast Cancer 2013; 13: 119-28. http://dx.doi.org/10.1016/j.clbc.2012.12.005
34. WERNERT N, GILLES F, FAFEUR V, BOUALI F, RAES MB et al. Stromal Expression of c-Ets1 Transcription Factor Correlates with Tumor Invasion. Cancer Res 1994; 54: 5683-5688.
35. VANDENBUNDER B, QUEVA C, DESBIENS X, WERNERT N, STEHELIN D. Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. Invasion Metastasis 1994-1995; 14: 198-209.